Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Mineralys Therapeutics In...

    NASDAQ: MLYS · Real-Time Price · USD
    13.73
    0.28 (2.08%)
    At close: Jun 17, 2025, 12:29 PM

    Mineralys Therapeutics Statistics

    Share Statistics

    Mineralys Therapeutics has 65.18M shares outstanding. The number of shares has increased by 26.46% in one year.

    Shares Outstanding

    n/a
    		 65.18M

    Shares Change (YoY)

    n/a
    		 26.46%

    Shares Change (QoQ)

    n/a
    		 26.15%

    Owned by Institutions (%)

    n/a
    		 91.99%

    Shares Floating

    n/a
    		 40.6M

    Failed to Deliver (FTD) Shares

    n/a
    		 2

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 6.16M, so 9.46% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.16M

    Short % of Shares Out

    n/a
    		 9.46%

    Short % of Float

    n/a
    		 12.5%

    Short Ratio (days to cover)

    n/a
    		 7.58

    Valuation Ratios

    The PE ratio is -3.36 and the forward PE ratio is -4.29. Mineralys Therapeutics's PEG ratio is -0.04.

    PE Ratio

    n/a
    		 -3.36

    Forward PE

    n/a
    		 -4.29

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 1.2

    PB Ratio

    n/a
    		 3.12

    P/FCF Ratio

    n/a
    		 -3.59

    PEG Ratio

    n/a
    		 -0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Mineralys Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 14.02, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 14.02

    Quick Ratio

    n/a
    		 14.02

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-3,486,470.59

    Employee Count

    n/a
    		 51

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 10.33% in the last 52 weeks. The beta is -0.18, so Mineralys Therapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.18

    52-Week Price Change

    n/a
    		 10.33%

    50-Day Moving Average

    n/a
    		 14.65

    200-Day Moving Average

    n/a
    		 12.87

    Relative Strength Index (RSI)

    n/a
    		 33.62

    Average Volume (20 Days)

    n/a
    		 940,031

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -192.4M

    Net Income

    n/a
    		 -177.81M

    EBITDA

    n/a
    		 -177.77M

    EBIT

    n/a
    		 -177.81M

    Earnings Per Share (EPS)

    n/a
    		 -3.66
    Full Income Statement

    Balance Sheet

    The company has 114.09M in cash and 0 in debt, giving a net cash position of 114.09M.

    Cash & Cash Equivalents

    n/a
    		 114.09M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -302.52M

    Total Assets

    n/a
    		 354.94M

    Working Capital

    n/a
    		 341.12M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -166.31M and capital expenditures -96K, giving a free cash flow of -166.41M.

    Operating Cash Flow

    n/a
    		 -166.31M

    Capital Expenditures

    n/a
    		 -96K

    Free Cash Flow

    n/a
    		 -166.41M

    FCF Per Share

    n/a
    		 -3.43
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    MLYS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for MLYS is $24, which is 78.3% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $24

    Price Target Difference

    n/a
    		 78.3%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 44.11

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist